Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI
NCT03326245Phase 1Completed
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism
- Start
- Jan 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by National Institute on Alcohol Abuse and Alcoholism. Primary endpoints: Standardized Uptake Value Ratio for [11C]Raclopride in Putamen, Percent BOLD Signal Change in the Anterior Cingulum and 1 more. Started Jan 2018; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03326245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03326245.